Aytu BioPharma, Inc. — Cyborg Score 4/10

Strategic Profile

The company is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease. Key prescription products include Adzenys XR-ODT and Cotempla XR-ODT for ADHD treatment across different age groups.

Cyborg Score Rationale

Aytu BioPharma reported a 16% year-over-year decline in revenue, totaling $13.9 million for the first quarter. With a market capitalization of $22.9M and an EPS of -$3.42, the company faces significant execution challenges despite analyst optimism.

Top Insights

• Q1 2026 revenue declined 16% year-over-year, signaling portfolio headwinds
• Rare disease focus (vascular Ehlers-Danlos Syndrome) provides differentiated pipeline opportunity
• Despite challenges, analysts maintain Strong Buy consensus as of Feb 2026
• TTM revenue of $62.6M with only 10.7M shares outstanding indicates concentrated ownership structure

Named Competitors

• ADHD & Pediatric Portfolio — Large-cap diversified pharma
• ADHD & Specialty Pediatrics — Global specialty pharma
• Injectable Specialty Pharma — Specialty drug delivery competitor

Recent Developments

• (October 2025) Presented at Planet MicroCap Showcase with product update
• (2025) Commercial availability of EXXUA announced in U.S. market
• (February 2026) Stock price target of $9.33 established by analyst consensus

Open the full interactive Aytu BioPharma, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.